Seroba Life Sciences

Investment decisions are made by the partnership group, which includes Alan O'Connell, Daniel O'Mahony, Jennifer McMahon, Bruno Montanari, and Catello Somma. Venture partner Jeanne Bolger, formerly of Johnson & Johnson Innovation — JJDC, contributes deal origination and board-level guidance but is not listed as a managing partner. The group operates as a consensus-driven investment committee rather than through a single CIO structure.

Yes. Seroba sources and leads investments across the European life sciences corridor, with named portfolio companies in Ireland, the UK, France, Germany, Italy, Belgium, and the Netherlands. While several portfolio companies seek FDA approval and have US operations, Seroba's investment mandate is rooted in European university spin-outs and early-stage ventures.

The firm's partners have generated multiple trade-sale and acquisition exits to large pharma and medtech strategics. These include Fusion Pharmaceuticals (acquired by AstraZeneca), Prexton Therapeutics (acquired by Lundbeck), Veryan Medical (acquired by Otsuka Medical), Covagen (acquired by Johnson & Johnson), and Apica Cardiovascular (acquired by Thoratec). The exit timeline spans from 2014 through the AstraZeneca acquisition of Fusion.

Seroba invests directly in portfolio companies as a lead or co-lead investor. There is no evidence it operates a fund-of-funds strategy or allocates capital to external GPs. Its model resembles a traditional venture capital firm targeting company-level equity positions rather than LP commitments to other funds.

Several partners have been with the firm since the early 2000s, including Alan O'Connell (2003) and Daniel O'Mahony (2009), which is unusually stable for a European venture firm. The group also blends operating backgrounds from corporate venture (J&J, Elan), investment banking (Deutsche Bank, Merrill Lynch), and technology transfer offices, giving it both syndicate networks and hands-on development expertise.

Seroba invests across the venture lifecycle, from seed and early stage through growth and late-stage rounds. The firm's active portfolio includes preclinical and clinical-stage biotech companies as well as commercial-stage medtech platforms, indicating it can support companies from initial laboratory data through regulatory approval and market entry.

Seroba does not publicly disclose its LP base or the origin of its capital. As a private venture capital firm, it likely raises capital from institutional investors, fund-of-funds, and potentially sovereign or development bodies active in European life sciences, but no specific fund closings or LP names appear in the sources consulted.